Influenza management with new therapies.
Adrenal Cortex Hormones
/ therapeutic use
Amides
/ therapeutic use
Antiviral Agents
/ adverse effects
Critical Care
Critical Illness
Dibenzothiepins
/ therapeutic use
Enzyme Inhibitors
/ therapeutic use
Humans
Influenza, Human
/ drug therapy
Morpholines
/ therapeutic use
Neuraminidase
/ antagonists & inhibitors
Oseltamivir
/ therapeutic use
Pyrazines
/ therapeutic use
Pyridines
/ therapeutic use
Pyridones
/ therapeutic use
Pyrimidines
/ therapeutic use
Pyrroles
/ therapeutic use
Respiration, Artificial
Triazines
/ therapeutic use
Zanamivir
/ therapeutic use
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
19
2
2020
medline:
4
2
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
Influenza represents a significant treatment burden to critical care services. A variety of treatment strategies exist, with more and more therapeutic avenues opening up as research progresses. We examined both pharmacological and supportive treatment strategies currently available to see how they might be applied in an ICU setting. Supportive care in Influenza centres around optimizing respiratory failure, particularly through well established and recognized ventilatory strategies. Noninvasive ventilation and high-flow nasal oxygen may have a limited role in selected patients under carefully monitored circumstances. Drug therapy exerts only a modest clinical effect and has been poorly studied in the critically ill, though there is some evidence to support the use of neuraminidase inhibitors (NAI) - particularly oseltamivir - as early as possible in this cohort. Newer agents have failed to demonstrate superiority over NAIs but may be useful options if the patient fails to respond or should resistant influenza strains emerge. Steroid therapy, in the absence of another indication, must be recommended against given the repeated trend towards increased mortality in this group. Influenza management is an evolving field of significant interest to any critical care provider. Currently, good respiratory supportive care and early enteral oseltamivir are the best supported treatment strategies. Further study in the intensive care setting will be needed before the use of novel agents can be recommended.
Identifiants
pubmed: 32068576
doi: 10.1097/MCP.0000000000000667
pii: 00063198-202005000-00006
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Amides
0
Antiviral Agents
0
Dibenzothiepins
0
Enzyme Inhibitors
0
Morpholines
0
Pyrazines
0
Pyridines
0
Pyridones
0
Pyrimidines
0
Pyrroles
0
Triazines
0
Oseltamivir
20O93L6F9H
baloxavir
4G86Y4JT3F
pimodivir
DFC121MXC3
Neuraminidase
EC 3.2.1.18
favipiravir
EW5GL2X7E0
Zanamivir
L6O3XI777I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-221Références
Reed C, Chaves SS, Kirley PD, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One 2015; 10: e0118369.
Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care 2019; 23:1–11.
Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines recommendations of the advisory committee on immunization practices - United States, 2016-17 influenza season. MMWR Recomm Reports 2016; 65:1–54.
Chiu APY, Dushoff J, Yu D, He D. Patterns of influenza vaccination coverage in the United States from 2009 to 2015. Int J Infect Dis 2017; 65:122–127.
Torres A, Martín-Loeches I, Menéndez R. Research in community-acquired pneumonia: the next steps. Intensive Care Med 2017; 43:1395–1397.
Martin-Loeches I, Nseir S, Valles J, Artigas A. From ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Reanimation 2013; 22:231–237.
Rodríguez A, Ferri C, Loeches IM, et al. Grupo Español de Trabajo Gripe A Grave (GETGAG)/Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) Working Group; 2009-2015 H1N1 SEMICYUC Working Group investigators. Risk factors for noninvasive ventilation failure in critically ill subjects with confirmed influenza infection. Respir Care 2017; 62:1307–1315.
Perner A, Gordon AC, De Backer D, et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med 2016; 42:1958–1969.
Simonis FD, Binnekade JM, Braber A, et al. PReVENT - protective ventilation in patients without ARDS at start of ventilation: study protocol for a randomized controlled trial. Trials 2015; 16:226.
Esan A, Hess DR, Raoof S, et al. Severe hypoxemic respiratory failure: part 1--ventilatory strategies. Chest 2010; 137:1203–1216.
Martin-Loeches I, Bos LD, Goligher EC. Will all ARDS patients be receiving mechanical ventilation in 2035? Yes. Intensive Care Med 2017; 43:568–569.
Cavalcanti AB, Suzumura EA, et al. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low peep on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 2017; 318:1335–1345.
Murias G, Lucangelo U, Blanch L. Patient-ventilator asynchrony. Curr Opin Crit Care 2016; 22:53–59.
Blanch L, Villagra A, Sales B, et al. Asynchronies during mechanical ventilation are associated with mortality. Intensive Care Med 2015; 41:633–641.
Moss M, Huang DT, Brower RG, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med 2019; 380:1997–2008.
Guérin C, Beuret P, Constantin JM, et al. A prospective international observational prevalence study on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study. Intensive Care Med 2018; 44:22–37.
Young D, Lamb SE, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. N Engl J Med 2013; 368:806–813.
Ferguson ND, Cook DJ, Guyatt GH, et al. Meade MO; OSCILLATE Trial Investigators; Canadian Critical Care Trials Group. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med 2013; 368:795–805.
Sukhal S, Sethi J, Ganesh M, et al. Extracorporeal membrane oxygenation in severe influenza infection with respiratory failure: a systematic review and meta-analysis. Ann Card Anaesth 2017; 20:14–21.
Martin-Loeches I, Schultz JM, Vincent JL, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med 2017; 43:48–58.
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Dutch-Belgian Mycosis study group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6:782–792.
Rodríguez AH, Avilés-Jurado FX, Díaz E, et al. SEMICYUC/GETGAG Working Group. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: a CHAID decision-tree analysis. J Infect 2016; 72:143–151.
Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007; 79:1577–1586.
Behzadi MA, Leyva-Grado VH. Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and middle east respiratory syndrome coronavirus infections. Front Microbiol 2019; 10:1327.
Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev 2014; 10:CD008965.
Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729–1737.
Katzen J, Kohn R, Houk JL, Ison MG. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis 2019; 1:52–58.
Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553–563.
Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198–1204.
Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother 2017; 72:2990–3007.
Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395–404.
Kromdijk W, Sikma MA, Van Den Broek MPH, et al. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. Intensive Care Med 2013; 39:977–978.
Hahn J, Choi JH, Chang MJ. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J Clin Pharmacy Ther 2017; 42:661–671.
South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346:f3039.
Pai MP, Lodise TP. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrob Agents Chemother 2011; 55:5640–5645.
Pillai VC, Han K, Beigi RH, et al. Population pharmacokinetics of oseltamivir in nonpregnant and pregnant women. Br J Clin Pharmacol 2015; 80:1042–1050.
Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 2019; 68:e1–e47.
Administration FAD. Tamiflu package insert, oserltamivir phosphate. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021246s038lbl.pdf. Accessed 25 November 2019.
Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654–1662.
Wester A, Shetty AK. Peramivir injection in the treatment of acute influenza: a review of the literature. Infect Drug Resist 2016; 9:201–214.
Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2013; 18:651–661.
Nakamura S, Miyazaki T, Izumikawa K, et al. Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: a multicenter randomized controlled study. Open Forum Infect Dis 2017; 4:1–8.
Lee J, Park JH, Jwa H, Kim YH. Comparison of efficacy of intravenous peramivir and oral oseltamivir for the treatment of influenza: systematic review and meta-analysis. Yonsei Med J 2017; 58:778–785.
Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 2017; 5:135–146.
Lina B, Boucher C, Osterhaus A, et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza Other Respi Viruses 2018; 12:267–278.
Hurt AC, Hardie K, Wilson NJ, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365:2541–2542.
Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opin Pharmacother 2019; 20:1711–1718.
Hung IFN, To KKW, Chan JFW, et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) Infection: an open-label randomized, controlled, phase IIb/III trial. Chest 2017; 151:1069–1080.
Martín-Loeches I, Bermejo-Martin JF, Vallés J, et al. SEMICYUC/REIPI/CIBERES H1N1 Working Group. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 2013; 39:693–702.
Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 2017; 11:240–246.
Tomassini J, Selnick H, Davies ME, et al. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994; 38:2827–2837.
Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res 2018; 160:109–117.
Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379:913–923.
Koshimichi H, Ishibashi T, Kawaguchi N, et al. Safety, tolerability, and pharmacokinetics of the novel antiinfluenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Investig 2018; 38:1189–1196.
Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018; 8:9633.
Takashita E, Kawakami C, Morita H, et al. On Behalf Of The Influenza Virus Surveillance Group Of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan. Eurosurveillance 2019; 24: doi: 10.2807/1560-7917.ES.2019.24.12.1900170.
doi: 10.2807/1560-7917.es.2019.24.12.1900170
Yang T. Baloxavir marboxil: the first cap-dependent endonuclease inhibitor for the treatment of influenza. Ann Pharmacother 2019; 53:754–759.
Ison MG. Antiviral treatments. Clin Chest Med 2017; 38:139–153.
Pielak RM, Chou JJ. Influenza M2 proton channels. Biochim Biophys Acta 2011; 1808:522–529.
Duwe S. Influenza viruses - antiviral therapy and resistance. GMS Infect Dis 2017; 5:Doc04.
Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane database Syst Rev 2006; (2):CD001169.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Japan Acad Series B 2017; 93:449–463.
Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Rese 2013; 100:446–454.
Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza a (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51:845–851.
Marathe BM, Wong SS, Vogel P, et al. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza a (H5N1) virus infection in mice. Sci Rep 2016; 6:26742.
Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the ebola virus disease pandemic. Disaster Med Public Health Prep 2015; 9:79–81.
Ormond L, Liu P, Matuszewski S, et al. The combined effect of oseltamivir and favipiravir on influenza a virus evolution. Genome Biol Evol 2017; 9:1913–1924.
Clark MP, Ledeboer MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 2014; 57:6668–6678.
Smee DF, Barnard DL, Jones SM. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res 2016; 136:45–50.
Medina RA, Stertz S, Manicassamy B, et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med 2013; 5:187ra70.
Trevejo JM, Asmal M, Vingerhoets J, et al. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther 2018; 23:335–344.
Finberg RW, Lanno R, Anderson D, et al. Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial. J Infect Dis 2019; 219:1026–1034.
McBride JM, Lim JJ, Burgess T, et al. Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza a virus challenge model. Antimicrob Agents Chemother 2017; 61: pii: e01154-17.
pii: e01154-17
Gupta P, Kamath AV, Park S, et al. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbs 2016; 8:991–997.
Omar Ali S, Takas T, Nyborg A, et al. Evaluation of MEDI8852, an antiinfluenza A monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob Agents Chemother 2018; 62: pii: e00694-18. doi: 10.1128/AAC.00694-18. Print 2018 Nov.
doi: 10.1128/aac.00694-18.
pii: e00694-18.
Hershberger E, Sloan S, Narayan K, et al. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine 2019; 40:574–582.
Moreno G, Rodríguez A, Reyes LF, et al. GETGAG Study Group. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med 2018; 44:1470–1482.
Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, Lim WS. Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis 2015; 212:183–194.
Yang JW, Fan LC, Miao XY, et al. Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. Clin Microbiol Infect 2015; 21:956–963.
Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care 2019; 23:99.
Lansbury L, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane database Syst Rev 2019; 2:CD010406.
Martin-Loeches I, Lisboa T, Rhodes A, et al. ESICM H1N1 Registry Contributors. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011; 37:272–283.
Lee N, Leo YS, Cao B, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J 2015; 45:1642–1652.
Alshabani K, Haq A, Miyakawa R, et al. Invasive pulmonary aspergillosis in patients with influenza infection: Report of two cases and systematic review of the literature. Expert Rev Respir Med 2015; 9:89–96.
Shah MM, Hsiao EI, Kirsch CM, et al. Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature. Diagn Microbiol Infect Dis 2018; 91:147–152.